This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 profit doubles to Rs 65 crore as revenue rises 40%
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved unaudited Q2 and half-year results for the quarter ended 30 Sep 2026; statutory auditors gave an unmodified review. Q2 revenue rose 40% to Rs 795.03 crore from Rs 567.53 crore, and profit after tax more than doubled to Rs 65.03 crore from Rs 30.00 crore. Half-year revenue was Rs 1,551.29 crore and profit Rs 129.51 crore, versus Rs 1,119.22 crore and Rs 63.96 crore. EPS was Rs 2.21. Pharma led growth.
Strong revenue and profit growth with wider margins supports the stock, but operating cash flow of Rs 8.32 crore was thin.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹795.0 Cr | ₹567.5 Cr | +40.1% |
| Operating profit | ₹81.78 Cr | ₹33.61 Cr | +143.3% |
| Profit after tax | ₹65.07 Cr | ₹29.97 Cr | +117.1% |
| EBITDA margin | 13.8% | 10.1% | +3.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.